The United States is currently going through a period of regulatory change within the Food and Drug Administration (FDA) and is experiencing diplomatic tension regarding Germany's pharmaceutical spending policies.

美國目前正處於食品藥物管理局 (FDA) 監管變更的階段，且在德國藥品支出政策方面面臨外交緊張局勢。

The FDA has started to reconsider several gene therapies that were previously rejected. For example, the agency agreed to re-evaluate a treatment for Hunter syndrome developed by Regenxbio. This condition causes cognitive decline because standard enzyme therapies cannot reach the brain. Similarly, UniQure was allowed to apply for a Huntington’s disease therapy that had been dismissed by a former commissioner. These changes have happened as several officials from the Trump era have left, which suggests that new leadership is more open to taking risks with these treatments.

FDA 已開始重新考慮數個先前被拒絕的基因療法。例如，該機構同意重新評估由 Regenxbio 開發的亨特症候群 (Hunter syndrome) 治療方案。由於標準酶療法無法到達大腦，這種疾病會導致認知能力下降。同樣地，UniQure 被允許申請一種曾被前任局長否決的亨廷頓舞蹈症 (Huntington’s disease) 療法。由於川普時代的幾位官員已離職，這些變動隨之而來，顯示新領導層更願意在這些治療方法上承擔風險。

At the same time, the U.S. Trade Representative has started an investigation into Germany under Section 301. This inquiry focuses on a plan by the German Ministry of Health to fix a $23 billion funding gap by changing the national healthcare system. The U.S. government wants to determine if the proposed discounts on medicines are unfair or discriminatory. Consequently, the German government has started to replace this plan after facing strong opposition from the pharmaceutical industry.

與此同時，美國貿易代表根據 301 條款對德國展開調查。此次調查重點在於德國衛生部計劃透過改變國家醫療體系，以填補 230 億美元的資金缺口。美國政府希望確定擬議的藥品折扣是否不公平或具有歧視性。因此，德國政府在面對製藥業強烈反對後，已開始替換該計劃。

In summary, the U.S. is changing its approach to high-risk gene therapies while closely monitoring European efforts to reduce pharmaceutical costs.

總結來說，美國在改變對高風險基因療法的處理方式，同時密切監控歐洲降低藥品成本的努力。